 The FDA approved Agios Pharmaceuticals Incs NASDAQ: AGIO Pyrukynd mitapivat for hemolytic anemia in adults with pyruvate kinase PK deficiency. Pyruvate kinase deficiency is an inherited metabolic disorder of the enzyme pyruvate kinase that affects red blood cells survival. 